Compare GLP-1 brands
Wegovy and Ozempic are semaglutide brands. Zepbound and Mounjaro are tirzepatide brands. The drug may be the same, but the product is not: approved use, dose schedule, age range and device can all change.
Source for this answer
Source: FDA labels and product records; source dates are listed below
Source: FDA labels and product records; source dates are listed below
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-12
What is each brand approved to treat?
Each row names an approved use. A dash means the product’s label does not include that use.
Scroll the table to compare all 9 brands.
| Approved use | WegovySemaglutideInjection | OzempicSemaglutideInjection | ZepboundTirzepatideInjection | MounjaroTirzepatideInjection | TrulicityDulaglutideInjection | VictozaLiraglutideInjection | SaxendaLiraglutideInjection | FoundayoOrforglipronTablet | RybelsusSemaglutideTablet |
|---|---|---|---|---|---|---|---|---|---|
| Weight reduction in adults | Yes | — | Yes | — | — | — | Yes | Yes | — |
| Weight reduction from age 12 | Yes | — | — | — | — | — | Yes | — | — |
| Blood sugar in adults with type 2 diabetes | — | Yes | — | Yes | Yes | Yes | — | — | Yes |
| Blood sugar from age 10 | — | — | — | Yes | Yes | Yes | — | — | — |
| Heart risk, with obesity or overweight | Yes | — | — | — | — | — | — | — | — |
| Heart risk, with type 2 diabetes | — | Yes | — | Yes | Yes | Yes | — | — | Yes |
| Kidney decline in type 2 diabetes | — | Yes | — | — | — | — | — | — | — |
| Obstructive sleep apnea | — | — | Yes | — | — | — | — | — | — |
| Noncirrhotic MASH with liver fibrosis | Yes | — | — | — | — | — | — | — | — |
Starting and highest labeled doses
Compare starting doses, dose steps and age ranges. Open a brand’s schedule for the timing and limits that apply to each use.
Scroll the table for all dose and age columns.
| Brand and form | Starts at | Highest dose | Dose steps | Youngest covered |
|---|---|---|---|---|
| WegovyInjectionTablet schedule | 0.25 mg | 7.2 mg | 6 | Age 12 |
| OzempicInjection | 0.25 mg | 2 mg | 4 | Adults only |
| ZepboundInjection | 2.5 mg | 15 mg | 2 | Adults only |
| MounjaroInjection | 2.5 mg | 15 mg | 6 | Age 10 |
| TrulicityInjection | 0.75 mg | 4.5 mg | 4 | Age 10 |
| VictozaInjection | 0.6 mg | 1.8 mg | 3 | Age 10 |
| SaxendaInjection | 0.6 mg | 3 mg | 5 | Age 12 |
| FoundayoTablet | 0.8 mg | 17.2 mg | 6 | Adults only |
| RybelsusTablet | 3 mg | 14 mg | 3 | Adults only |
How to read these comparisons
What matters first
- Medicine
- Some brands share an ingredient. Approved uses and doses can still differ.
- Form
- The tables identify injections and tablets separately.
- Schedule
- Each product has its own dose steps and limits. Open the full schedule for details.
- Sources
- The source list below includes the records and their dates.
Brand details and guides
Find each brand’s medicine, product details and available guides.
Compare two brands
Open a comparison to see how the products differ and which trials or labels it uses.
- Mounjaro against Ozempic, line by line — different medicines; see the evidence and its limits.
- Wegovy against Ozempic, line by line — one drug substance, two labels.
- Mounjaro against Zepbound, line by line — one drug substance, two labels.
- Zepbound against Ozempic, line by line — different medicines; see the evidence and its limits.
- Wegovy against Mounjaro, line by line — different medicines; see the evidence and its limits.
- Foundayo against Zepbound, line by line — different medicines; see the evidence and its limits.
What do the drug pages cover instead?
These brand pages stay on the label: who it covers, what schedule it prints, what device it comes in. The drug pages answer the other half.
- The semaglutide dosage chart covers the drug itself, including vial and syringe arithmetic no brand pen needs.
- The tirzepatide dosage chart does the same for the drug in Zepbound and Mounjaro.
- Wegovy against Zepbound, side by side covers their weight-management comparison and the trial behind it.
- Compare brand costs and coverage shows published prices and who qualifies for each offer.
Questions readers ask
What is the best brand of GLP-1?
Is Zepbound better than Ozempic?
What are the top 10 GLP-1 drugs?
Which GLP-1 provider is the best?
- Wegovy (semaglutide) injection and tablets — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-12FDA label
- Wegovy (semaglutide) Prescribing Information, revised 06/2026 — Drugs@FDA NDA 215256/S-025retrieved 2026-08-12FDA label
- FDA approval letter, NDA 215256 — Wegovy (semaglutide) injection, chronic weight management in adultsretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-005 — Wegovy in pediatric patients aged 12 years and olderretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-011 — Wegovy cardiovascular risk reduction indication (SELECT)retrieved 2026-08-12FDA label
- FDA accelerated approval letter, NDA 215256/S-024 — Wegovy for noncirrhotic MASH with stage F2 to F3 fibrosisretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215256/S-029 — Wegovy injection 7.2 mg once-weekly doseretrieved 2026-08-12FDA label
- FDA approval letter, NDA 218316 — Wegovy (semaglutide) tablets, oral dosage formretrieved 2026-08-12FDA label
- Ozempic (semaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Drugs@FDA approval history — NDA 209637, Ozempic (semaglutide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 209637 — Ozempic (semaglutide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-003 — Ozempic cardiovascular event risk reduction in type 2 diabetes with established cardiovascular disease (SUSTAIN 6)retrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-025 — Ozempic for reducing sustained eGFR decline, end-stage kidney disease and cardiovascular death in type 2 diabetes with chronic kidney diseaseretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 209637/S-009 — addition of a third Ozempic maintenance dose, 2 mg once weeklyretrieved 2026-08-12FDA label
- Zepbound (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Zepbound (tirzepatide) Prescribing Information, revised 02/2026 — Drugs@FDA NDA 217806/S-042retrieved 2026-08-12FDA label
- FDA approval letter, NDA 217806 — Zepbound (tirzepatide) injection, chronic weight management in adultsretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 217806/S-013 — Zepbound for moderate to severe obstructive sleep apnearetrieved 2026-08-12FDA label
- Mounjaro (tirzepatide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-13FDA label
- Drugs@FDA approval history — NDA 215866, Mounjaro (tirzepatide) injectionretrieved 2026-08-12FDA label
- FDA approval letter, NDA 215866 — Mounjaro (tirzepatide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215866/S-039 — expansion of the Mounjaro type 2 diabetes indication to pediatric patients aged 10 years and older (trial I8F-MC-GPGV)retrieved 2026-08-12FDA label
- FDA supplement approval letter, NDA 215866/S-044 and S-045 — Mounjaro heart-risk reduction and 2.5 mg for ongoing blood sugar controlretrieved 2026-09-13FDA label
- Trulicity (dulaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Trulicity (dulaglutide) Prescribing Information, revised 03/2026 — Drugs@FDA BLA 125469/S-065retrieved 2026-08-13FDA label
- FDA licensing letter, BLA 125469 — Trulicity (dulaglutide), glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, BLA 125469/S-051 — expansion of the Trulicity glycemic-control indication to pediatric patients 10 years of age and olderretrieved 2026-08-13FDA label
- FDA supplement approval letter, BLA 125469/S-033 — Trulicity indication for reducing major adverse cardiovascular events in type 2 diabetes (REWIND)retrieved 2026-08-13FDA label
- Drugs@FDA via openFDA — every application containing dulaglutide, which is BLA 125469 and nothing elseretrieved 2026-08-13FDA label
- Victoza (liraglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Victoza (liraglutide) Prescribing Information, revised 10/2025 — Drugs@FDA NDA 022341/S-046retrieved 2026-08-13FDA label
- FDA approval letter, NDA 022341 — Victoza (liraglutide) injection, glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 022341/S-031 — expansion of the Victoza type 2 diabetes age range to patients 10 years and older (ELLIPSE)retrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 022341/S-027 — Victoza indication for reducing major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease (LEADER)retrieved 2026-08-13FDA label
- Drugs@FDA via openFDA — applications containing liraglutide, including the approved abbreviated new drug applications from Sandoz, Teva, Lupin, Hikma, Biocon, Mylan, Fresenius Kabi and others, and the label each one carriesretrieved 2026-08-13FDA label
- Saxenda (liraglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Saxenda (liraglutide) Prescribing Information, revised 02/2026 — Drugs@FDA NDA 206321/S-025retrieved 2026-08-13FDA label
- FDA approval letter, NDA 206321 — Saxenda (liraglutide) injection, chronic weight management in adultsretrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 206321/S-012 — addition of a Saxenda pediatric indication for ages 12 and older (trial NN8022-4180)retrieved 2026-08-13FDA label
- FOUNDAYO (orforglipron) tablet, film coated [Eli Lilly and Company] — DailyMed SPL version 10, published 2026-08-13, revised 07/2026retrieved 2026-09-06FDA label
- Rybelsus and Ozempic (semaglutide) tablets — one FDA-approved Prescribing Information covering both names (DailyMed)retrieved 2026-08-20FDA label
- Rybelsus (semaglutide) tablets Prescribing Information, revised 01/2026 — Drugs@FDA NDA 213051/S-030retrieved 2026-08-13FDA label
- FDA approval letter, NDA 213051 — Rybelsus (semaglutide) tablets, glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, NDA 213051/S-024 — Rybelsus indication for reducing major adverse cardiovascular events in adults with type 2 diabetes at high riskretrieved 2026-08-13FDA label
- FDA drug shortages database via openFDA — Rybelsus 3 mg, 7 mg and 14 mg tablets, status To Be Discontinued, to be replaced by Ozempic tabletsretrieved 2026-08-13FDA label